Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFT0HU)

• Drug Name: [3H]resolvin D1 Drug Info
• Synonyms: OIWTWACQMDFHJG-LDOXQWQISA-N; RvD1; [3H]-RvD1; GTPL4356; GTPL3934; SCHEMBL13150511; (4Z,7S,8S,9E,11E,13Z,15E,17S,19Z)-7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoic; OIWTWACQMDFHJG-LDOXQWQISA-N; (4Z,7S,8S,9E,11E,13Z,15E,17S,19Z)-7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoic acid; resolvin D1

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 73755062
  TTD Drug ID: DMFT0HU

Molecule-Related Drug Atlas

Drug(s) Targeting G-protein coupled receptor 32 (GPR32)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LXA4	DMGSVL0	Discovery agent	N.A.	Investigative	[2]
RvD1-ME	DM8EZTM	Discovery agent	N.A.	Investigative	[4]

Drug(s) Targeting Transformation-sensitive protein p120 (TRPA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[5]
LY3526318	DMFXNQM	Chronic low-back pain	MG30	Phase 2	[6]
HX-100	DMFRM15	Diabetic neuropathy	8C0Z	Phase 1	[7]
NPPB	DMFIWAN	Discovery agent	N.A.	Investigative	[8]
acetaldehyde	DMJFKG4	Discovery agent	N.A.	Investigative	[9]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[10]
icilin	DMYVOL9	Discovery agent	N.A.	Investigative	[11]
4-oxo-nonenal	DMPX1J9	Discovery agent	N.A.	Investigative	[12]
dibutyl phthalate	DMEDGKO	Discovery agent	N.A.	Investigative	[13]
prostaglandin A2	DMWC4X8	Discovery agent	N.A.	Investigative	[14]

Drug(s) Targeting FMLP-related receptor I (FPR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
humanin	DMUAPNF	Alzheimer disease	8A20	Preclinical	[15]
LXA4	DMGSVL0	Discovery agent	N.A.	Investigative	[2]
PMID22607879CR-(-)-5f	DM7OJ5Q	Discovery agent	N.A.	Investigative	[16]
aspirin-triggered resolvin D1	DMOP941	Discovery agent	N.A.	Investigative	[4]
fMet-Leu-Phe	DMQ391A	N. A.	N. A.	Investigative	[17]
RvD1-ME	DM8EZTM	Discovery agent	N.A.	Investigative	[4]
pyrazolone, 1	DMLFQKU	Discovery agent	N.A.	Investigative	[18]
quin-C7	DM1CYWB	Discovery agent	N.A.	Investigative	[19]
aspirin triggered lipoxin A4	DMLBSNP	Discovery agent	N.A.	Investigative	[20]
quin-C1	DMVQYWS	Discovery agent	N.A.	Investigative	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
FMLP-related receptor I (FPR2)	TTOJ1NF	FPR2_HUMAN	Agonist	[2]
G-protein coupled receptor 32 (GPR32)	TT7OCUB	GPR32_HUMAN	Agonist	[2]
Transformation-sensitive protein p120 (TRPA1)	TTELV3W	TRPA1_HUMAN	Inhibitor (gating inhibitor)	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4356).
• [2] Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1660-5.
• [3] Resolvin D1 attenuates activation of sensory transient receptor potential channels leading to multiple anti-nociception. Br J Pharmacol. 2010 Oct;161(3):707-20.
• [4] Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am J Pathol. 2012 May;180(5):2018-27.
• [5] TRPV1-mediated itch in seasonal allergic rhinitis. Allergy. 2009 May;64(5):807-10.
• [6] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] NPPB structure-specifically activates TRPA1 channels. Biochem Pharmacol. 2010 Jul 1;80(1):113-21.
• [9] Transient receptor potential A1 mediates acetaldehyde-evoked pain sensation. Eur J Neurosci. 2007 Nov;26(9):2516-23.
• [10] An ion channel essential for sensing chemical damage. J Neurosci. 2007 Oct 17;27(42):11412-5.
• [11] ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell. 2003 Mar 21;112(6):819-29.
• [12] Transient receptor potential A1 is a sensory receptor for multiple products of oxidative stress. J Neurosci. 2008 Mar 5;28(10):2485-94.
• [13] TRPA1 and TRPV1 activation is a novel adjuvant effect mechanism in contact hypersensitivity. J Neuroimmunol. 2009 Feb 15;207(1-2):66-74.
• [14] Cox-dependent fatty acid metabolites cause pain through activation of the irritant receptor TRPA1. Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):12045-50.
• [15] N-Formylated humanin activates both formyl peptide receptor-like 1 and 2. Biochem Biophys Res Commun. 2004 Nov 5;324(1):255-61.
• [16] Synthesis, enantioresolution, and activity profile of chiral 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones as potent N-formyl peptide receptor agonists. Bioorg Med Chem. 2012 Jun 15;20(12):3781-92.
• [17] Multiple domains of the N-formyl peptide receptor are required for high-affinity ligand binding. Construction and analysis of chimeric N-formyl peptide receptors. J Biol Chem. 1993 Aug 25;268(24):18167-75.
• [18] Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3713-8.
• [19] Pharmacological characterization of a novel nonpeptide antagonist for formyl peptide receptor-like 1. Mol Pharmacol. 2007 Oct;72(4):976-83.
• [20] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 223).
• [21] A novel nonpeptide ligand for formyl peptide receptor-like 1. Mol Pharmacol. 2004 Nov;66(5):1213-22.